Conmed Corp CNMD
We take great care to ensure that the data presented and summarized in this overview for CONMED Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CNMD
View all-
Black Rock Inc. New York, NY4.99MShares$379 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$268 Million0.0% of portfolio
-
Earnest Partners LLC Atlanta, GA2.78MShares$211 Million0.91% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.54MShares$117 Million0.02% of portfolio
-
Bank Of America Corp Charlotte, NC1.37MShares$104 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.37MShares$104 Million0.62% of portfolio
-
State Street Corp Boston, MA1.31MShares$99.3 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3936KShares$71.1 Million0.07% of portfolio
-
Westwood Holdings Group Inc Dallas, TX882KShares$67 Million0.5% of portfolio
-
Sei Investments CO Oaks, PA871KShares$66.1 Million0.08% of portfolio
Latest Institutional Activity in CNMD
Top Purchases
Top Sells
About CNMD
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Insider Transactions at CNMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 20
2024
|
Richard Glaze Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
118
-31.47%
|
$8,260
$70.69 P/Share
|
Nov 20
2024
|
Richard Glaze Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
375
+50.0%
|
-
|
Nov 07
2024
|
Curt R Hartman President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
24,303
-70.86%
|
$1,798,422
$74.76 P/Share
|
Nov 07
2024
|
Curt R Hartman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+46.66%
|
$1,530,000
$51.3 P/Share
|
Sep 05
2024
|
Charles Farkas Director |
SELL
Payment of exercise price or tax liability
|
Direct |
534
-2.56%
|
$39,516
$74.31 P/Share
|
Sep 05
2024
|
Charles Farkas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+4.57%
|
$39,000
$39.64 P/Share
|
Aug 01
2024
|
Edward A. Clifford VP Global Manufacturing |
SELL
Payment of exercise price or tax liability
|
Direct |
122
-24.4%
|
$7,930
$65.34 P/Share
|
Aug 01
2024
|
Edward A. Clifford VP Global Manufacturing |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+50.0%
|
-
|
Jun 14
2024
|
Stanley W Peters Iii President AS and AET |
SELL
Open market or private sale
|
Direct |
4,000
-98.45%
|
$284,000
$71.82 P/Share
|
Jun 14
2024
|
Stanley W Peters Iii President AS and AET |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+49.61%
|
$164,000
$41.93 P/Share
|
May 31
2024
|
Brian Concannon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+3.04%
|
-
|
May 31
2024
|
Jerome J. Lande Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+7.26%
|
-
|
May 31
2024
|
Charles Farkas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+1.5%
|
-
|
May 31
2024
|
David M Bronson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+1.77%
|
-
|
May 31
2024
|
John L Workman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+1.46%
|
-
|
May 31
2024
|
Barbara J Schwarzentraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+7.25%
|
-
|
May 31
2024
|
La Verne H Council Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+7.8%
|
-
|
May 31
2024
|
Martha Goldberg Aronson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
302
+2.47%
|
-
|
May 13
2024
|
David M Bronson Director |
BUY
Open market or private purchase
|
Direct |
1,350
+7.58%
|
$97,200
$72.09 P/Share
|
May 08
2024
|
Barbara J Schwarzentraub Director |
BUY
Open market or private purchase
|
Indirect |
1,442
+50.0%
|
$99,498
$69.26 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 93.2K shares |
---|---|
Grant, award, or other acquisition | 454 shares |
Open market or private purchase | 7.79K shares |
Payment of exercise price or tax liability | 71.2K shares |
---|---|
Open market or private sale | 6.3K shares |